The new TB antimicrobial, developed by researchers and fellows of CONICET together with Laboratorios Richmond, obtained last February the Patent in the US and now received another of the European Patent Office (EPO).
Read more +
Laboratorios Richmond signed an investment agreement with Colombian Laboratorios Expofarma, with the objective of increasing and developing present operations both in Colombia and other markets where both companies currently commercialize their line of products.
Read more +
In it we provide insight into the components of our integral management which are involved in a secure, continuous and sustainable development of our company
Compliance or adherence in medical treatments is extremely important, especially in cardiovascular diseases where it reduces rates of hospitalization and mortality remarkably. Among strategies to improve adherence, it is possible to find medication that reduces daily intake, presenting several drugs in only one pill (polypill).
More than 60% of the 140.000 Sofosbuvir units the health ministry bought, correspond to Richmond’s product. Its more accessible price allows for a higher number of infected Hepatitis C patients in a critic state to receive the treatment.